The Implications of HHS-OIG’s New General Compliance Program Guidance for Life Sciences Companies

On December 5, Skadden presented the webinar “The Implications of HHS-OIG’s New General Compliance Program Guidance for Life Sciences Companies.” Firm speakers included Washington, D.C. litigation head Jennifer Bragg and life sciences and health care partners Avia Dunn and Maya Florence. A partner from Dovetail Consulting Group served as an external speaker. The panelists discussed key aspects of the Office of Inspector General, U.S. Department of Health and Human Services’ (HHS-OIG’s) General Compliance Program Guidance, including elements that may pose particular challenges for life sciences companies, how HHS-OIG’s comments compare to recent DOJ policies, expectations regarding risk assessments and data utilization, governance considerations for compliance committees and boards of directors, and expanded subject areas to be evaluated under compliance programs.